Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials | PLOS ONE
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network | Haematologica
Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis | PLOS ONE
Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP
![Serum free light chain analysis - Davids - 2010 - American Journal of Hematology - Wiley Online Library Serum free light chain analysis - Davids - 2010 - American Journal of Hematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/939f9e71-c16d-4bf8-9449-da9629dcc93a/mfig001.jpg)